Vor Biopharma
37 hedge funds and large institutions have $183M invested in Vor Biopharma in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 10 closing their positions.
525% more call options, than puts
Call options by funds: $361M | Put options by funds: $57.8M
100% more capital invested
Capital invested by funds: $91.9M → $183M (+$91.5M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
6% more funds holding
Funds holding: 35 → 37 (+2)
0.69% more ownership
Funds ownership: 2.28% → 2.97% (+0.69%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$20.1M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$15.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.3M |
| 4 |
ACM
Ariose Capital Management
Central, Hong Kong,
Hong Kong
|
+$4.43M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$10.3M |
| 2 |
HF
HRT Financial
New York
|
-$768K |
| 3 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$567K |
| 4 |
Jane Street
New York
|
-$383K |
| 5 |
Renaissance Technologies
New York
|
-$354K |
VOR Hedge Fund Activity: Q3 2025 in Review
37 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q3 2025, worth a combined $183M — up 100% from $91.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VOR positions and 10 closed out — a net gain of 2 holders — while 9 added to existing stakes and 15 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $20.1M. The largest seller was 5AM Venture Management, exiting entirely with an estimated $10.3M sold.
- 37 institutional investors held Vor Biopharma (VOR) as of Q3 2025, up from 35 in Q2 2025.
- Funds reported $183M of Vor Biopharma stock for Q3 2025, up 100% quarter-over-quarter.
- 12 funds opened new Vor Biopharma positions in Q3 2025 and 10 closed out, a net change of +2 holders.
- The largest Vor Biopharma buyer in Q3 2025 was VR Adviser, an estimated $20.1M added.
- The largest Vor Biopharma seller in Q3 2025 was 5AM Venture Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2025.